Oncopeptides AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was SEK 66.374 million. Operating loss was SEK 344.836 million compared to SEK 399.332 million a year ago. Net loss was SEK 24.116 million compared to SEK 401.041 million a year ago. Basic loss per share from continuing operations was SEK 0.32 compared to SEK 6.79 a year ago. For the half year, sales was SEK 85.729 million. Operating loss was SEK 692.167 million compared to SEK 696.208 million a year ago. Net loss was SEK 258.780 million compared to SEK 698.370 million a year ago. Basic loss per share from continuing operations was SEK 3.63 compared to SEK 12.2 a year ago.